Abstract
Introduction
Osteoporosis continues to be an attractive therapy area for large
pharmaceutical companies due to its high prevalence rate and unmet need.
Globally, sales for osteoporosis drugs grew 7.0% year-on-year from 2004 to
$9.6 billion in 2008 driven by strong performance of the bisphosphonate class.
Key reasons to purchase this research
- Understand current and future osteoporosis drug market dynamics
- Gain insight into the unmet needs of current osteoporosis treatment and to
what extent pipeline drugs will address these issues
- Evaluate the sales forecasts of marketed, generic, and key pipeline drugs
to 2018 in the US, Japan, France, Germany, Italy, Spain, and the UK
| 
View Cart
